CEA Monitoring Among Patients in Multi-institutional Adjuvant G.I. Therapy Protocols

摘要: The Gastrointestinal Tumor Study Group (GITSG) has since 1975 included protocols for monitoring carcinoembryonic antigen (CEA) levels in its colorectal cancer adjuvant trials. Among the 563 patients on colon study (GI 6175) and 207 rectal 7175), one third had preoperative CEA determinations more than 90% some postoperative monitoring. Colon whose was greater 5 ng/ml a probability of recurring those values were lower (33% versus 18% recurrence with 21 months minimum follow-up; p < 0.05). prognostic value apparent only Dukes' C1 tumors. Preoperative not significance among adenocarcinoma patients. Although elevated after resection either or rectum cancers strongly associated subsequent tumor recurrence, no single value, arbitrarily defined as “elevated”, provided an adequate screening test both high sensitivity specificity. Postoperative elevations predictive when part steadily rising trend. In study, median monthly increase disease-free estimated to be zero, relapsed 5.8%. corresponding estimates protocol zero 7.8%. Only 36 344 14 94 (15%) exhibited rate 3% per month over entire period observation. Two thirds studies showed this higher. patterns rise individual quite varied, however, rates established our are used guidelines patient management.